We are live on ! Find out more
SM

Sabby Management Portfolio holdings

AUM $45.1M
1-Year Est. Return 74.25%
This Fund
S&P 500
This Quarter Est. Return
-4.22%
1 Year Est. Return
-74.25%
3 Year Est. Return
-95.86%
5 Year Est. Return
-99.36%
10 Year Est. Return
-99.46%
AUM
$740M
AUM Growth
+$30.5M
Cap. Flow
-$239M
Cap. Flow %
-32.31%
Top 10 Hldgs %
67%
Holding
218
New
56
Increased
59
Reduced
50
Closed
36

Top Buys

Rank Stock Value
1
BTBT icon
Bit Digital
BTBT
+$40.7M
2
SLAI
SOLAI Ltd ADS
SLAI
+$15.2M
3
VRPX
Virpax Pharmaceuticals, Inc. Common Stock
VRPX
+$7.02M
4
FLUX icon
Flux Power
FLUX
+$6.05M
5
VXX icon
iPath Series B S&P 500 VIX Short-Term Futures ETN
VXX
+$5.87M

Top Sells

Rank Stock Value
1
LNAI
Lunai Bioworks
LNAI
+$7.71M
2
ATOS icon
Atossa Therapeutics
ATOS
+$4.06M
3
ATER icon
Aterian
ATER
+$4M
4
ASXC
Asensus Surgical, Inc.
ASXC
+$2.95M
5
RDHL
Redhill Biopharma
RDHL
+$2.34M

Sector Composition

Rank Sector Weight
1 Healthcare 6.89%
2 Financials 5.45%
3 Technology 3.65%
4 Industrials 1.84%
5 Communication Services 0.92%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PMCB icon
151
PUT
PharmaCyte Biotech
PMCB
$6.33M
$140K 0.02%
+441
New +$1.55K
PALI icon
152
Palisade Bio
PALI
$351M
$139K 0.02%
70
– –
FCEL icon
153
CALL
FuelCell Energy
FCEL
$1.57B
$134K 0.02%
+7
New +$1.39K
LFWD icon
154
PUT
ReWalk Robotics
LFWD
$19.6M
$127K 0.02%
10
-38
-79% -$4.72K
EQOS
155
PUT
DELISTED
EQONEX LIMITED Ordinary Shares
EQOS
$119K 0.02%
367
-121
-25% -$614
CRDF icon
156
PUT
Cardiff Oncology
CRDF
$63.6M
$113K 0.02%
170
+3
+2% +$19
EVOK
157
DELISTED
Evoke Pharma
EVOK
$107K 0.01%
569
+240
+73% +$40.5K
CTXR icon
158
PUT
Citius Pharmaceuticals
CTXR
$13.7M
$100K 0.01%
+20
New +$1K
NBRV
159
PUT
DELISTED
Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV
$94K 0.01%
32
-17
-35% -$480
IO
160
CALL
DELISTED
ION Geophysical Corporation
IO
$92K 0.01%
692
+192
+38% +$271
PHIO icon
161
Phio Pharmaceuticals
PHIO
$11.7M
$83K 0.01%
377
-102
-21% -$21.3K
HCDIW
162
DELISTED
Harbor Custom Development, Inc. Warrant
HCDIW
$83K 0.01%
148,975
-123,128
-45% -$87.7K
ROI
163
DELISTED
RiskOn International, Inc. Common Stock
ROI
$77K 0.01%
+487
New +$68.3K
BKYI
164
BIO-key International
BKYI
$4.61M
$70K 0.01%
111
+17
+18% +$10K
TCDA
165
CALL
DELISTED
Tricida, Inc. Common Stock
TCDA
$68K 0.01%
146
– –
VTGN icon
166
PUT
VistaGen Therapeutics
VTGN
$9.55M
$67K 0.01%
+8
New +$695
PPBT
167
PUT
Purple Biotech
PPBT
$1.28M
$57K 0.01%
1
-9
-90% -$8.72K
ASLN
168
PUT
DELISTED
ASLAN Pharmaceuticals Limited American Depositary Shares
ASLN
$54K 0.01%
+8
New +$910
EVFM
169
PUT
DELISTED
Evofem Biosciences, Inc. Common Stock
EVFM
$54K 0.01%
48
-15
-24% -$188
NBRV
170
DELISTED
Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV
$44K 0.01%
1,469
-842
-36% -$23.8K
CBAT icon
171
CBAK Energy Technology Ltd
CBAT
$43.6M
$41K 0.01%
17,548
-157,549
-90% -$524K
NTBL
172
CALL
DELISTED
Notable Labs, Ltd. Ordinary Shares
NTBL
$41K 0.01%
6
– –
ATHX
173
PUT
DELISTED
Athersys, Inc. Common Stock
ATHX
$41K 0.01%
12
+4
+50% +$152
SRGA
174
DELISTED
Surgalign Holdings, Inc. Common Stock
SRGA
$35K ﹤0.01%
+1,064
New +$39K
TTNP
175
PUT
DELISTED
Titan Pharmaceuticals
TTNP
$34K ﹤0.01%
9
-55
-86% -$2.41K
5 6
7
8 9

Similar funds

CG
Circumference Group Little Rock, Arkansas $44.6M AUM 5.21% 1-Year Est. Return
OC
Optimas Capital Central, Hong Kong $44.5M AUM 24.43% 1-Year Est. Return
ICCON
Investment Counsel Company of Nevada Las Vegas, Nevada $44.5M AUM 21.97% 1-Year Est. Return
PCM
Prentice Capital Management Greenwich, Connecticut $45.7M AUM 2.65% 1-Year Est. Return
CAS
CTC Alternative Strategies Chicago, Illinois $44M AUM 43.15% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
CTC
Corundum Trust Company Sioux Falls, South Dakota $43.8M AUM 20.07% 1-Year Est. Return

Sabby Management's Q3 2021 Portfolio in Review

As of Q3 2021, Sabby Management held 218 positions worth $740M, up 4.3% from $709M the previous quarter. Its ten largest holdings account for 67% of the portfolio.

Sabby Management withdrew a net $239M in Q3 2021, closing 36 positions and reducing 50 holdings. Its most notable exit was Atossa Therapeutics, an estimated $4.06M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 6.9% of assets, down from 10% a quarter earlier, followed by Financials and Technology.

Against the trend, Sabby Management opened a new position in Bit Digital worth $30.5M.

  • Sabby Management's largest Q3 2021 buy was Bit Digital: 4,216,310 shares worth $30.5M.
  • Sabby Management added most to Virpax Pharmaceuticals, Inc. Common Stock in Q3 2021, an estimated $7.02M increase.
  • Sabby Management's biggest Q3 2021 reduction was Lunai Bioworks, cutting an estimated $7.71M.
  • Sabby Management fully exited Atossa Therapeutics in Q3 2021, selling an estimated $4.06M.
  • Sabby Management's ten largest holdings make up 67% of its $740M portfolio in Q3 2021.
  • Sabby Management opened 56 new positions and closed 36 in Q3 2021.
  • Sabby Management's portfolio value rose 4.3% quarter-over-quarter to $740M.

Based on Sabby Management's 13F filing for Q3 2021, filed 15 Nov 2021.